Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tagraxofusp + Azacitidine Maintenance Post-HCT for CD123+ AML/MDS
NCT06498973Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Jan 2025
- Primary completion
- Apr 2027
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tagraxofusp in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by City of Hope. Primary endpoints: Incidence of adverse events, Dose limiting toxicities and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
tagraxofusp
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06498973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06498973.